All In Biotech

Drug Trial Radar · NCT07225634

A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain

An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Mar 2027

Study completion Apr 2027

Sponsor

Lead sponsor
AFT Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
Collaborators
HungaroTrial
First posted
Nov 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Combogesic® IV is an intravenous medicine (given by vein) containing a combination of two pain relief (analgesic) medicines called ibuprofen and acetaminophen. The goal of this clinical trial is to study the way that the body processes and clears the intravenous infusion of Combogesic® IV and that it is safe to be used in children and adolescents between the ages of 2 and \<17 years. What will the study involve for participants? * Combogesic® IV will be administered every 6 hours as necessary with a maximum of 4 doses within a 24-hour period as an intravenous infusion for about 15 minutes. * Participants will receive Combogesic® IV for a minimum of 12 hours (2 doses) up to a maximum of 5 days (20 doses). Dosing will be dependent on body weight. * If pain is not sufficiently controlled by Combogesic® IV, opioids may be used as supplementary pain relief at the discretion of the study doctor. * Have their blood samples collected before dosing and at specific times after dosing. The amount of study drug in the blood will be measured, and safety assessments (including blood and urine samples) will be done. * Rate the study drug at the end of the treatment. It is expected that Combogesic® IV will be well tolerated in children and adolescents and that the pharmacokinetics findings will be similar as compared with adults.

Conditions

  • Acute Pain

Interventions

  • Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)Drug

    Acetaminophen 1000 mg and Ibuprofen 300 mg per 100 mL solution for intravenous infusion administered as a 15-minute infusion, every 6 hours, as necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent adverse events (TEAEs) associated with exposure to Combogesic® IV in pediatric patientsTime frame: From start of exposure to Combogesic® IV up to 7 days after last dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Semmelweis University

    Budapest, Hungary · Recruiting

  • Petz Aladar County Teaching Hospital

    Győr, Hungary · Recruiting

  • University of Pecs

    Pécs, Hungary · Recruiting

  • Zala County St. Rafael Hospital

    Zalaegerszeg, Hungary · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.